• 1
    Hesketh PJ, Gralla RJ, Dubious A, Tonato M. Methodology of anti-emetic trials. Support Care Cancer 1998; 6: 2217.
  • 2
    Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM et al. On the receiving end – patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 2038.
  • 3
    Roila F, Tonato M, Ballatori E, Del Favero A. Comparative studies of various antiemetic regimens. Support Care Cancer 1996; 4: 27080.
  • 4
    De Boer-Dennert M, De Wit R, Schmitz PI, Djontono J, V Beurden V, Stoter G et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997; 76: 105561.
  • 5
    Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 1997; 5: 30713.
  • 6
    Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004; 100: 22618.
  • 7
    Olver I, Paska W, Depierre A, Seitz J-F, Stewart DJ, Goedhals L et al; on behalf of the Ondansetron Delayed Emesis Study Group. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol 1996; 7: 94552.
  • 8
    Kaizer L, Warr D, Hoskins P, Latreille J, Lofters W, Yau J et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 12: 10507.
  • 9
    Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 15707.
  • 10
    Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98: 247382.
  • 11
    Olver IN. Aprepitant in antiemetic combinations to prevent chemotherapy induced nausea and vomiting. Int J Clin Prac 2004; 58: 2016.
  • 12
    Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97: 30908.
  • 13
    Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, De Wit R et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. The aprepitant protocol 052 Study Group. J Clin Oncol 2003; 21: 411219.
  • 14
    McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL et al. Effects of the neurokinin 1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharm Ther 2003; 74: 1724.
  • 15
    Blum RA, Majumdar A, McCrea J, Busillo J, Orlowski LH, Panebianco D et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003; 25: 140719.
  • 16
    Warr DG, Eisenberg P, Hesketh PJ, Gralla RJ, Raftopoulos H, Gabriel M et al. Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetogenic chemotherapy: a randomized double-blind trial in 866 patients. 2004 ASCO Annual Meeting Proceedings. J Clin Oncol 2004; 22: 14S.
  • 17
    Herrstedt J, Hesketh P, Warr D, Muss H, Gabriel M, Rodgers A et al. Randomized double-blind trial comparing the effect of an aprepitant regimen versus a standard antiemetic regimen during four cycles of moderately emetogenic chemotherapy. Ann Oncol 2004; 15 (Suppl 3): iii218.
  • 18
    Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 2005; 13: 8596.
  • 19
    Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB et al. Patient-tailored antiemetic treatment with 5-hydroxytrptamine type 3 receptor antagonists according to cytochrome P-450 2wD6 genotypes. J Clin Oncol 2002; 20: 27657.
  • 20
    Tremblay PB, Kaiser R, Sezer O, Rosler N, Schelenz C, Possinger K et al. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer. J Clin Oncol 2003; 21: 2147215.